Key result
Ticlopidine (500 mg daily) potently inhibited ADP- and collagen-induced platelet aggregation and synergistically potentiated prostacyclin inhibition in men with stable angina.
Why the study?
Does ticlopidine reduce platelet reactivity in middle-aged men with stable angina pectoris?
RCT (n=38)
Double-blind
Does ticlopidine reduce platelet reactivity in middle-aged men with stable angina pectoris?
Ticlopidine effectively inhibits platelet aggregation induced by ADP and collagen and synergizes with prostacyclin in men with stable angina.
No takes yet. Share an insight, caveat, or question.
Supports ticlopidine for platelet inhibition in stable angina; extends RCT evidence to this population.
Berglund et al. (1985) conducted an RCT in Stable incapacitating angina pectoris (n=38). Ticlopidine vs. Placebo was evaluated on Platelet function including in vitro platelet reactivity to aggregating agents. Ticlopidine (500 mg daily) potently inhibited ADP- and collagen-induced platelet aggregation and synergistically potentiated prostacyclin inhibition in men with stable angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: